FORT LAUDERDALE, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform combination therapy optimized for solid tumor cancers, today announced that it will present late-breaking Phase 1 clinical data at this year’s American Association for Cancer Research (AACR) Annual Meeting 2024, being held in San Diego, California from April 5 to 10, 2024.
The presentation, titled, “Systemic responses to SYNC-T therapy: in situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC),” will include results from the SV-102 Phase 1 trial, and the therapy’s potential impact on the treatment landscape for metastatic castrate-resistant prostate cancer. This late-breaking presentation marks the first time that the Company will have publicly shared data from its clinical trials of the SYNC-T therapy platform.
Presentation Details are:
Title: Systemic responses to SYNC-T therapy: in situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC)
Presenter: Charles J. Link, M.D.
Date: April 7, 2024
Time: 3:00 – 5:00pm PT
Session Title: Cancer Vaccines: Ready for Prime Time?
Location: San Diego Convention Center, San Diego, California
About Syncromune®
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform technology optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T™, a novel and personalized combination drug/device therapy platform. SYNC-T is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in Phase 1 trials. Syncromune is headquartered in Fort Lauderdale, FL, USA. For more information, please visit www.syncromune.com.
About SYNC-T™
Syncromune® is developing SYNC-T™, a personalized in situ combination drug/device platform designed to educate T cells and stimulate the immune system to treat metastatic solid tumors. SYNC-T utilizes a combination approach of in situ vaccination via device-induced cryolysis and intratumoral infusion of a multi-target biologic drug, aiming to synchronize the timing and location of tumor antigen release with the functional activation of immune cells. This is designed to activate the immune system and combat immune suppression, resulting in patient-specific T cell education. The expansion of anti-cancer T cells can enable the immune system to recognize and destroy cancer in the treated tumor as well as in metastases throughout the body.
This press release includes forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained in this press release or expressed orally in connection herewith that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, forward-looking statements can be identified by phrases such as “plans,” “intends,” “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, statements herein that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Accordingly, you should not place undue reliance on our forward-looking statements. The forward-looking statements contained in this press release or expressed orally in connection herewith are made only as of the date of this press release and we undertake no obligation to update the forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law. None of Syncromune, Inc., its affiliates or their respective directors, officers, employees or agents gives any representation or warranty, express or implied, as to: (i) the achievement or reasonableness of future projections, management targets, estimates or prospects contained in this press release; or (ii) the accuracy or completeness of any information contained in this press release, any other written information or oral information provided in connection herewith or any data that any of them generates. This press release was prepared by us for informational purposes only and does not constitute an offer, or solicitation of an offer, to sell any securities at any time. None of Syncromune’s securities have been registered under the Securities Act of 1933, as amended, or any state securities law. Such securities have not been approved or disapproved by the Securities and Exchange Commission or by any state securities regulatory authority, nor has the Securities and Exchange Commission or any such state authority passed on the accuracy or adequacy of this press release. Any representation to the contrary is a criminal offense. Some of the information contained in this press release may be derived from information provided by industry sources. We believe that such information is accurate and that the sources from which it has been obtained are reliable; however, we cannot guarantee the accuracy of such information and have not independently verified such information.
Corporate Contact
Danielle Hobbs
EVP, Corporate Communications
Syncromune, Inc.
media@syncromune.com
Media Contact
Michael Rubenstein
LifeSci Communications
media@syncromune.com
